Lakefront Biotherapeutics (LKFT) Cash & Current Investments (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash & Current Investments for 13 consecutive years, with $3.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 48.83% year-over-year to $3.5 billion; the TTM figure through Mar 2026 stood at $3.5 billion (down 48.83% YoY), while the FY2025 annual figure was $3.6 billion, down 49.34% from the prior year.
• Cash & Current Investments held at $3.5 billion in Q1 2026 per LKFT's latest filing, from $3.5 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $7.7 billion in Q1 2024 and bottomed at -$2.5 billion in Q3 2022.
• Historically, Cash & Current Investments has averaged $4.5 billion across 5 years, with a median of $4.1 billion in 2023.
• On a YoY basis, Cash & Current Investments climbed as much as 538.14% in 2022 and fell as far as 65.86% in 2022.
• Lakefront Biotherapeutics' Cash & Current Investments stood at $1.8 billion in 2022, then soared by 115.79% to $4.0 billion in 2023, then slipped by 15.96% to $3.3 billion in 2024, then increased by 4.76% to $3.5 billion in 2025, then grew by 0.05% to $3.5 billion in 2026.
• Business Quant data shows LKFT's Cash & Current Investments at $3.5 billion in Q1 2026, $3.5 billion in Q4 2025, and $7.3 billion in Q3 2025.